Document Detail

The next step in cardiovascular protection.
MedLine Citation:
PMID:  14980229     Owner:  NLM     Status:  MEDLINE    
While aggressive interventional therapy and anti-thrombotic therapy have revolutionized the management of acute coronary syndromes (ACS), defined as acute myocardial infarction (MI) or unstable angina (UA), long-term event rates remain high. Elevated lipids, inflammation and infection have each been implicated as additional mechanisms contributing to instability of vulnerable plaques. The new frontier in ACS management has focussed on treatment of these components of vascular disease. Preliminary trials have shown that early treatment with statins after ACS reduces coronary events but additional studies are needed to confirm this benefit. Furthermore, it is not clear what degree of low-density lipoprotein cholesterol (LDL-C) lowering is needed to stabilize the ACS patient. Chlamydia pneumoniae has been implicated in the development of coronary heart disease (CHD) but the results of preliminary trials investigating anti-chlamydial antibiotics have been inconsistent. Therefore, the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT TIMI 22) trial has been designed specifically to determine whether standard LDL-C reduction (with pravastatin 40 mg) provides a similar clinical benefit to more aggressive LDL-C reduction (with atorvastatin 80 mg). In 4162 ACS patients over a 2-year period, this trial will also evaluate the long-term effect of the quinolone antibiotic, gatifloxacin, in reducing cardiovascular events.
Christopher P Cannon
Related Documents :
686939 - Cholesterol embolization: a complication of angiography.
24217829 - A less aggressive therapeutic option for electrical storm.
1572059 - Cost and health implications of cholesterol lowering.
11115459 - Plasma homocysteine and severity of thoracic aortic atherosclerosis.
8902159 - Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acut...
16674359 - Prevention of heart disease: is ldl reduction the outcome of choice? no, there is more.
2729109 - Simple, rapid method for quantification of tricuspid regurgitation by two-dimensional e...
8449229 - Effects of gallopamil, a ca2+ channel blocker in models of ventricular arrhythmia in dogs.
19122579 - Optimizing outcomes in coronary ct imaging.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Atherosclerosis. Supplements     Volume:  4     ISSN:  1567-5688     ISO Abbreviation:  Atheroscler Suppl     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2004-02-24     Completed Date:  2004-03-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100973461     Medline TA:  Atheroscler Suppl     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  3-9     Citation Subset:  IM    
TIMI Study Group, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angina, Unstable / etiology,  prevention & control*
Anti-Bacterial Agents / therapeutic use*
Anticholesteremic Agents / therapeutic use
Chlamydia Infections / complications,  drug therapy
Chlamydophila pneumoniae
Cholesterol, LDL / blood
Clinical Trials as Topic
Heptanoic Acids / therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Myocardial Infarction / etiology,  prevention & control*
Pravastatin / therapeutic use
Pyrroles / therapeutic use
Recurrence / prevention & control
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock.
Next Document:  Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcom...